25.3 C
Vientiane
Wednesday, October 8, 2025
spot_img
Home Blog Page 980

Vietnam to Block Telegram in Early June

Vietnam to Block Telegram in Early June
A man uses the messaging app Telegram on an Ipad in Hanoi on May 23, 2025. (Photo by Nhac NGUYEN / AFP)

AFP – Internet service providers in Vietnam must block the Telegram messaging app in the country before early June after a request by police, the government said on 23 May.

Medtronic chairman and CEO Geoff Martha to speak at Bernstein’s Strategic Decisions Conference

GALWAY, Ireland, May 24, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein’s 41st Strategic Decisions Conference on Thursday, May 29, 2025.

Geoff Martha, Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT (10:00 a.m. CDT). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

A live webcast of the presentation and Q&A session will be available on May 29, 2025, by clicking on the Events link at http://investorrelations.medtronic.com. An archive of the presentation and Q&A session will be available on the same webpage later in the day.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts
Erika Winkels
Public Relations
+1-763-526-8478

Ryan Weispfenning
Investor Relations
+1-763-505-4626

 

 

MindHYVE.ai™ Brings Agentic Intelligence and AGI Innovation to Africa’s Premier Tech Summit

NEWPORT BEACH, Calif., May 24, 2025 /PRNewswire/ — MindHYVE™, a global pioneer in Agentic Artificial Intelligence (AI) and Artificial General Intelligence (AGI), will headline the Connected Africa Summit 2025, taking place May 26–29 at the Diamonds Leisure Beach & Golf Resort in Diani, Kenya.

Bill Faruki, Founder & CEO of MindHYVE.ai™, to Deliver Opening Remarks, Keynote Address, and AGI Masterclass at Connected Africa Summit 2025
Bill Faruki, Founder & CEO of MindHYVE.ai™, to Deliver Opening Remarks, Keynote Address, and AGI Masterclass at Connected Africa Summit 2025

Founder & CEO Bill Faruki will lead the summit’s discourse with three high-profile engagements:

  • Opening Remarks
    Launching the summit by outlining a bold vision for Africa-led intelligence architectures, sovereignty in AI development, and scalable digital autonomy.
  • Keynote Address
    “The Agentic Age: Swarm Intelligence and Africa’s Digital Future” — a forward-looking narrative on how agentic systems, swarm coordination, and AGI frameworks can reshape public infrastructure, services, and innovation pipelines.
  • 90-Minute Masterclass
    “Rearchitecting Intelligence: Agentic AI and the Next Frontier for Africa” — a hands-on, domain-specific session exploring healthcare, finance, and governance through the lens of large reasoning models and next-generation AI agents built on MindHYVE’s Ava-Fusion™ platform.

Comment from Bill Faruki, CEO of MindHYVE.ai™

“Africa isn’t following the AI revolution — it’s shaping it. At MindHYVE.ai™, we believe Agentic AI isn’t just about automation; it’s about architecting new systems of intelligence—driven by swarm dynamics and powered by large reasoning models—that are inclusive, sovereign, and purpose-built for the future of this continent.”

About the Connected Africa Summit 2025

As Africa’s flagship convening for digital transformation, the Connected Africa Summit gathers 2,000+ global leaders, from heads of state and ICT ministers to Fortune 500 executives and innovation accelerators. The 2025 edition spotlights sovereign AI, intelligence infrastructure, and the continent’s role in shaping global AGI development.

To learn about this event please visit https://connected.go.ke/

About MindHYVE.ai™

MindHYVE.ai™ is redefining the boundaries of intelligence by engineering autonomous systems and deploying domain-specific AGI agents across real-world sectors. Powered by the Ava-Fusion™ large reasoning model and architected for agent coordination, swarm intelligence, and adaptive autonomy, MindHYVE’s technology stack is revolutionizing law, medicine, finance, education, and governance.

With operations in North America, Asia, and now soon in Africa, MindHYVE.ai™ is on a mission to democratize access to transformative intelligence and architect the infrastructure for post-scarcity economies. Backed by HYVE Labs, the company continues to shape the future of agentic systems on a global scale.

Website: www.mindhyve.ai | Email:hello@mindhyve.ai | Contact: +1 (949) 200-8668

Media Contact
Marc Ortiz
Email: marc.ortiz@mindhyve.ai

Built with intelligence, Guided by humanity
Built with intelligence, Guided by humanity

 

 

Global Times: Why China’s economy so stable despite external challenges?

BEIJING, May 24, 2025 /PRNewswire/ — “In April, China’s economic data showed resilience despite intensifying external challenges, especially as the exports expanded rapidly. Why is the economy so stable amid external challenges?” This is a question that a reader of people.cn posted.

On May 19, China released economic figures for April, with “stronger than expectations” emerging as the dominant reaction among analysts. Some foreign media outlets commented that the economy has “showed surprising resilience, a sign that government support measures may have cushioned the impact of a trade war with the US that threatens to derail momentum in the world’s second-largest economy.”

Why is the Chinese economy so stable despite external challenges? The answer can be found from two examples.

Strong internal dynamics 

Also on May 19, Chinese tech giant Huawei unveiled two laptops powered by HarmonyOS, marking the debut of its self-developed operating system on personal computers. A day later, another Chinese tech firm Xiaomi announced that its first self-developed 3-nanometer mobile chip, Xring O1, has entered mass production.

No form of containment or suppression can disrupt China’s pace in achieving self-dependent innovation and growth. It is precisely such confidence and self-reliance that enabled the economy to deliver a result “exceeding expectations.”

In early April, the People’s Daily reporters visited Yiwu, the world’s largest wholesale market for small commodities in East China’s Zhejiang Province, where store owners were busy building their brands and enhancing product quality.

Shifting from the mode of original equipment manufacturer to building their own brands, Yiwu brands unite for overseas expansion with Yiwu Selection Store.

In January, the first Yiwu Selection Store was launched, and secured signed orders totaling 120 million yuan ($16.67 million) on the first day of its grand opening. Later in February, the first Yiwu Selection Store in Europe was opened in Venice, Italy. In just a few months, the project has helped more than 190 brands in Yiwu to increase revenue by over 100 million yuan and expand cooperation with 11 countries. Diversification shields them against unilateralist challenges.

Many export-oriented manufacturers in Yiwu also proactively engage in innovation and extend their industrial chains to enhance their competitiveness. A Yiwu merchant encapsulated this sentiment well, “With quality products and extensive sales channels, we’re unafraid of changes.”

It is precisely the internal momentum of numerous individual market entities that has contributed to the overall economic upward trend.

Overall capacity elevated

In April, China’s total import and export of goods in yuan-denominated terms expanded 5.6 percent year-on-year, according to data released by the General Administration of Customs on May 9.

The country’s goods exports rose 9.3 percent year-on-year last month. In terms of export categories, technology-intensive mechanical and electrical products demonstrated sustained market competitiveness. In the first four months, exports of these goods grew by 9.5 percent year-on-year.

From the perspective of business entities, private export-oriented companies have effectively navigated external challenges through strategies like market diversification. During the same period, private sector imports and exports expanded by 6.8 percent year-on-year.

Meanwhile, a country’s foreign trade does not exist in isolation. China’s rapid export growth in April reflects the elevation of its overall capacity thanks to the high-quality economic development.

For instance, as an ultra-large economy, China has maintained its manufacturing dominance for 15 consecutive years, and boasts one of the world’s largest consumer markets with great growth potential. These structural advantages underscore the country’s strong capacity to deal with various risks and challenges.

In addition, China unswervingly promotes economic structural adjustment and shifting between old and new growth drivers, develops new quality productive forces according to local conditions, moves faster to create a new pattern of development, and vigorously strengthens domestic circulation to keep itself well-positioned for pursuing development. All of these efforts have provided critical guarantees for dealing with drastic changes in external environment.

Stepped-up policy support 

China has stepped up macroeconomic adjustments. A meeting of the Political Bureau of Communist Party of China (CPC) Central Committee held on September 26, 2024 decisively deployed a package of incremental policies, resulting in an economic trajectory characterized by high growth at the beginning, a slowdown in the mid-phase, and a rebound near the end of last year.

Several key meetings including the Central Economic Work Conference held at the end of 2024, this year’s two sessions and the meeting of the Political Bureau of CPC Central Committee held on April 25 have made arrangements on economic work. While maintaining policy continuity, these policies put efforts on stabilizing employment, business, market expectations, which have played an important role in sustaining economic recovery.

The authorities have rolled out policies such as interest rate and reserve requirement ratio cuts, accelerating the integration of domestic and foreign trade, and expanding comprehensive pilot programs to accelerate the services industry’s opening-up. Along with the implementation of the new policies, China has conditions, capability and confidence to deal with any risks and challenges.

An economy’s true strength is most evident during adversity, and this resilience further reinforces confidence and resolve in achieving growth targets.

International institutions have upgraded their forecasts for China’s economic growth recently. Many multinational executives now regard China as a synonym for “certainty.”

As always, China’s economy grows in storms and waves, and gets stronger through hard times. While future international environments will remain volatile and uncertain, history has proven and will continue to prove that China’s recovery is underpinned by solid fundamentals, policy support, consumption potential and innovation-driven dynamism.

We have the confidence and determination that China’s development will have a bright future.

https://www.globaltimes.cn/page/202505/1334729.shtml

 

/DISREGARD RELEASE: Celltrion/

We are advised by Celltrion that journalists and other readers should disregard the news release, Celltrion’s YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths, issued 21-May-2025 over PR Newswire.

Robots and Human-Centric AI Dazzle at Opening of BEYOND Expo 2025

Pioneering Asian tech unveiled as industry leaders call for global cooperation

MACAO, May 23, 2025 /PRNewswire/ — The 5th BEYOND Expo opened it door to visitors today at The Venetian® Macao’s Cotai Expo as over 800 pioneering Asian companies and tech leaders gathered to showcase leading innovations in robotics, human-centric AI, mixed reality and climate solutions under the theme “Empowering Asia, Connecting the World”. VIPs and industry leaders from across Asia came together to share their perspectives about the importance of international cooperation, cross-cultural dialogue and globalization to create mutually beneficial economic and investment opportunities.

Robots attract attention at BEYOND Expo 2025 Source: BEYOND Expo
Robots attract attention at BEYOND Expo 2025 Source: BEYOND Expo

Asian companies displayed pioneering tech across a wide range of sectors from AI, HealthTech, Clean Energy and Robotics to Lifestyle Tech, SportsTech, FinTech and more, wowing business owners, investors and dignitaries who had come to Macao for the Expo. Realising BEYOND Expo’s vision of “Empowering Asia, Bridging the World” the BGlobal Summit opened with a keynote from H.E. Djauhari Oratmangun, Indonesian Ambassador to China, who highlighted the growing economic and investment opportunities in Indonesia and across Asia. Takeo Kawamura – 76th Chief Cabinet Secretary of Japan – highlighted the importance of international cooperation, cross-cultural dialogue, and Japan’s evolving approach to globalization. Throughout the Expo’s exhibitor booths and event stages, conversations focused on the need to leverage human-centered tech solutions to tackle global challenges.

Xpeng Aeroht demonstrates AEROHT at BEYOND Expo 2025 Source: BEYOND Expo
Xpeng Aeroht demonstrates AEROHT at BEYOND Expo 2025 Source: BEYOND Expo

Panel sessions today included Green Building Conference; BGlobal Summit; Japan Tech Forum; Middle East-Asia Forum; Asia-Europe Tech Forum; International Industrial Design Forum; Founder Talk; Demo session; ORIGIN Southeast Asia Tech Forum; and SheTech Summit.

Encouraging Innovation – BEYOND Expo Awards

BEYOND Expo co-founders Jason Ho and Dr. Lu Gang presented BEYOND Best Choice awards to 25 companies. Since its inception in 2021, the BEYOND Awards have received more than 1,500 nominations, of which more than 200 innovative pioneers have been included in the list. This year’s award combines technological breakthroughs, business potential, social value and other dimensions.

In order to nurture startups, BEYOND Expo offers Innovation Awards to support entrepreneurs and discover outstanding individuals or technical products and services. The BEYOND Impact Awards honor companies that are driving meaningful change in the realms of environment, society, economy, and technology in line with the United Nation’ 17 Sustainable Development Goals. Other awards include Gen Z Innovators: The New Force, which focuses on Gen Z entrepreneurs in China looking out towards Asia, BEYOND Medical Technology Excellence Awards and BEYOND Healthy Living Products Innovation Awards which focuses on excellence in medical technology companies and health consumption products.

Visitors flock to BEYOND Expo 2025 Source: BEYOND Expo
Visitors flock to BEYOND Expo 2025 Source: BEYOND Expo

Visit BEYOND Expo 2025 at The Venetian® Macao’s Cotai Expo

BEYOND Expo 2025 is being held at The Venetian® Macao’s Cotai Expo. Since opening, Cotai Expo has been a leading conference, meetings and exhibition venue in Macao, and is one of the largest MICE venues in Asia, with approximately 71,000 square metres of exhibition space. It is also part of Sands® Resorts Macao, which attracts top event planners from around the world due to its 150,000 square metres of MICE space, world-class entertainment venues, award-winning accommodation, spectacular recreation and leisure options, unrivalled shopping experiences, and dynamic dining options. Sands Resorts Macao’s newest hotel, located within The Londoner® Macao, is Londoner Grand, which marks a bold new chapter in luxury for discerning travellers and event planners.

A full list of participating companies can be found here: BEYOND EXPO 2025

About BEYOND Expo

The BEYOND International Technology Innovation Expo (BEYOND Expo) is Asia’s leading annual technology event. Serving as a dynamic platform since 2021, BEYOND Expo not only showcases global technological innovations but also provides a unique opportunity to foster innovation upgrades across diverse industries and regions.

BEYOND Expo has attracted participation from Asia’s Fortune 500 companies, multinational corporations, unicorn companies, and emerging startups. Through a multifaceted approach involving expos, summits, and various activities, BEYOND Expo has successfully cultivated an innovative ecosystem, propelling collective development in the Asia-Pacific region and the global technology innovation industry. www.beyondexpo.com

 

 

 

TWSC Debuts at COMPUTEX 2025: Empowering AI with Full-Stack Storage Solutions

TAIPEI, May 23, 2025 /PRNewswire/ — From May 20 to 23, 2025, TWSC made its debut at COMPUTEX 2025, one of the world’s leading technology exhibitions, under the theme “Transcending Intelligence, Ascending Full-Stack Solutions.” The company showcased a full range of storage products and solutions designed to support next-generation AI and computing applications.

TWSC showcases its full-scenario storage product portfolio and solutions at the event.
TWSC showcases its full-scenario storage product portfolio and solutions at the event.

As AI adoption accelerates, storage technology is becoming more scenario-driven. TWSC provides tailored “One Solution for One Scenario” services based on its full-chain capabilities in chips, algorithms, and application scenarios, accurately addressing the diverse needs of smart terminals, industrial control, servers, and other fields.

Full-Stack Storage Matrix Unleashes Efficiency

TWSC highlighted high-throughput, low-latency solutions at the event, including PCIe 5.0 SSDs, DDR5, eMMC, UFS, and LPDDR series. Combining performance and efficiency, these products enable AI inference and edge computing applications.

According to TWSC’s 2024 annual report, the company reported revenue of RMB 4.773 billion, a 168.74% increase year-over-year. Embedded storage sales reached RMB 843 million, rising by 1730.6%, while high-speed PCIe SSD sales grew 979%, becoming a major growth driver.

The company now offers scenario-based solutions across enterprise, embedded, consumer, and industrial applications, building a strong foundation for global growth through advanced storage modules.

Full-Stack Self-Developed Capabilities Build Competitive Edge

To enhance control over the industrial chain, TWSC has developed an integrated “wafer-to-product” scenario-based service capability, enabling differentiation through media analysis, chip design, firmware optimization, and packaging control.

TWSC uses its “5+1+N” global supply chain network to ensure smooth coordination across R&D, production, and delivery. With a robust validation system and adaptive quality control, the company aligns product quality closely with customer needs.

From chips to scenarios, and data to value — TWSC’s participation highlights the shift of storage technology from basic functions to intelligent services. By integrating industrial resources and expanding application scenarios, the company is building an open and collaborative innovation ecosystem for smart storage.

About TWSC: Shenzhen Techwinsemi Technology Co., Ltd. (Stock Code: 001309.SZ) was established in 2008 and specializes in integrated circuit solutions for storage controllers and modules. The product line covers four major series: SSD, embedded storage, DDR, and portable storage — offering reliable storage solutions for high-value applications such as smart terminals, data centers.

For more information please visit https://en.twsc.com.cn/, and follow TWSC on Facebook and Linkedin.

Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting

SHANGHAI, May 23, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including phase Ib/II clinical study data of 9MW2821 (Bulumtatug Fuvedotin, BFv), a novel Nectin-4 targeting ADC, in combination with Toripalimab in locally advanced or metastatic uroepithelial carcinoma to be presented as oral presentation, and clinical study data of 7MW3711 and 9MW2921, a novel B7-H3 targeting ADC and a novel Trop-2 targeting ADC respectively, to be presented as poster presentations. The study of 9MW2821 was the only selected Chinese oral presentation in the field of urothelial carcinoma at this meeting.

Nectin-4 ADC (9MW2821):

In the phase Ib/II clinical study of 9MW2821 in combination with Toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma (la/mUc), a total of 40 patients with previously untreated for la/mUC were enrolled in the study and were treated with 9MW2821 (1.25 mg/kg) and Toripalimab (240 mg).

As of December 19, 2024, the objective response rate (ORR) was 87.5% and the confirmed ORR was 80%. The disease control rate (DCR) was 92.5%. Median progression-free survival (PFS) and duration of response (DoR) have not been achieved. No new safety signals of 9MW2821 or Toripalimab were observed in this study.

9MW2821 stands out as the first clinical-stage drug candidate among Chinese companies for this specific target. And it’s the first Nectin-4 targeting ADC to disclose clinical efficacy data in cervical, esophageal, and breast cancers. Currently, 3 Phase III pivotal clinical trials are ongoing. Its monotherapy and combination therapy with Toripalimab for urothelial carcinoma have been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. It has also been granted Fast Track Designations (FTD) for 3 indications and Orphan Drug Designation (ODD) for 1 indication by the U.S. Food and Drug Administration (FDA).

B7-H3 ADC (7MW3711):

7MW3711 has enrolled 43 patients as of January 2, 2025 in a phase I/II clinical study in patients with advanced solid tumors. During the dose-escalation phase, dose-limiting toxicity (DLT) was not observed and the maximum tolerated dose (MTD) has not been reached. In patients evaluated at doses of 4.5 mg/kg or higher, the ORR for esophageal cancer, ovarian cancer, and prostate cancer was 33.3%, 60.0%, and 50.0%, respectively, and the DCR was 100%.

In the phase I/II clinical study in lung cancer patients, 37 lung cancer patients were enrolled as of January 8, 2025, including 16 small cell lung cancer (SCLC) patients and 21 non-small cell lung cancer (NSCLC) patients. Common grade ≥3 adverse reactions were neutrophil count decreased, white blood cell count decreased, anemia, lymphocyte count decreased, and platelet count decreased. Among the 25 patients who received 7MW3711 at a dose of 4.5 mg/kg or greater and completed at least one tumor evaluation, the ORR was 36.0% and the DCR was 96.0%; of these, the ORR and DCR were 62.5% and 100.0%, respectively, for patients with small-cell lung cancer at a dose of 4.5 mg/kg. Among squamous lung cancer (Sq-NSCLC) patients with a B7-H3 H-score >5, the ORR and DCR were 37.5% and 87.5%, respectively.

The study results suggest that 7MW3711 has a tolerable safety profile and good anti-tumor activity in patients with advanced tumors such as lung, esophageal, prostate and ovarian cancers.

7MW3711 was developed with Mabwell’s Interchain-Disulfide Drug Conjugate (IDDC™) platform. It consists of an innovative antibody molecule, a novel linker, and a novel payload: Mtoxin™, which is a topoisomerase I inhibitor. It has been granted ODD by the FDA for the treatment of SCLC.

Trop-2 ADC (9MW2921):

In the first-in-human clinical study in patients with advanced solid tumors, a total of 39 patients were enrolled as of November 12, 2024. The most common ≥3 grade adverse were stomatitis, anemia, white blood cell count decreased, neutropenia, lymphocyte count decreased, etc. The ORR of 3.0 mg/kg dose group was 42.1% and the DCR was 84.2%. Under this dose level, the ORR and DCR was 75% and 100% for endometrial cancer, 50% and 75% for HR+/HER2- breast cancer, 50% and 100% for gastric cancer, 25% and 100% for non-squamous non-small cell lung cancer.

The study result suggests that 9MW2921 has a tolerable safety profile and good anti-tumor activity in patients with advanced tumors.

9MW2921 was developed with Mabwell’s Interchain-Disulfide Drug Conjugate (IDDC™) platform. It consists of an innovative antibody molecule, a novel linker, and a novel payload: Mtoxin™, which is a topoisomerase I inhibitor. 

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 16 pipeline products in different stages based on a world-class and state-of-the-art R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for market approval, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for “Significant New Drugs Development”, 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects. Mabwell’s Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base in Shanghai and the ADC commercialized manufacturing base in Taizhou are under construction. Our mission is “Explore Life, Benefit Health” and our vision is “Innovation, from ideas to reality”. For more information, please visit www.mabwell.com/en.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.